ReviewFrontiers in neurology2025
Mechanisms and potential therapeutic molecular targets in blood-brain barrier disruption following subarachnoid hemorrhage: a review of early brain injury.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Resveratrol attenuates pyroptosis and neuroinflammation by inhibiting the TLR4/NF-κB/AIM2 pathway in ischemic stroke rats.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subarachnoid hemorrhage (SAH) is a devastating stroke characterized by acute onset, severe symptoms, and a poor prognosis. A series of pathological changes occur within 72 h after SAH, leading to early brain injury (EBI). Blood-brain barrier (BBB) disruption is a key factor contributing to the EBI progression. When the BBB is compromised, detrimental substances and immune cells have the potential to infiltrate brain tissues, and a range of mechanisms contribute to the disruption of the BBB following SAH. This review provides a comprehensive overview of the current knowledge regarding the underlying mechanisms and potential therapeutic targets in BBB disruption during EBI following SAH. It focuses on the dysfunction of endothelial cells, tight junctions, astrocytes, and pericytes; the specific molecular targets for EBI after SAH; and new emerging treatments for BBB disruption in EBI after SAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.